0 results

Patient Corner

Anatomical Illustrations

More

Last reference updates

  • Mar 24, 2017 - FDA Drug Updates

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Bavencio (avelumab) is approved as the first treatment for Merkel cell carcinoma, a rare form of skin cancer

Read more
  • Mar 22, 2017 - FDA Drug Updates

FDA approved Xadago (safinamide) for Parkinson’s disease

Xadago (safinamide) approved as an add-on therapy for the treatment of Parkinson’s disease

Read more
  • Mar 23, 2017 - MedWatch Drug Updates

FDA Safety Alert: breast implants associated with risk of developing anaplastic large cell lymphoma

FDA has identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL)

Read more
  • Mar 23, 2017 - MedWatch Drug Updates

FDA safety alert - Absorb GT1 Bioresorbable Vascular Scaffold associated with increased risk of CV events

FDA is investigating increased risk of major cardiac events observed in patients receiving treatment with Bioresorbable Vascular Scaffold

Read more
  • Mar 2, 2017 - FDA Drug Updates

FDA approved Odactra for house dust mite allergies

FDA approved Odactra, first sublingual allergen extract for the treatment of house dust mite allergies

Read more
  • Mar 1, 2017 - FDA Drug Updates

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

FDA approved Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog

Read more
  • Mar 15, 2017 - MedWatch Drug Updates

Recall of SynchroMed Implantable Infusion Pump by Medtronic due to hindered drug delivery during priming bolus procedure

Medtronic recalled the SynchroMed Implantable Infusion Pumps because of unintended delivery of drugs during a priming bolus procedure

Read more
  • Feb 16, 2017 - FDA Drug Updates

FDA approves Siliq (brodalumab) for psoriasis

Siliq (brodalumab) is indicated in patients who are candidates for systemic therapy or phototherapy

Read more
  • Feb 15, 2017 - FDA Drug Updates

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Parsabiv (etelcalcetide) can be administered intravenously at the end of the hemodialysis session

Read more
  • Mar 10, 2017 - MedWatch Drug Updates

Warning against the use of static preservation solution due to potential contamination with bacteria

FDA urges not to use static preservation solution due to potential contamination with Pantoea and Enterococcus bacteria

Read more